Abstract:Precision medicine relies on the idea that, for a particular targeted agent, only a subpopulation of patients is sensitive to it and thus may benefit from it therapeutically. In practice, it is often assumed based on preclinical data that a treatment-sensitive subpopulation is known, and moreover that the agent is substantively efficacious in that subpopulation. Due to important differences between preclinical settings and human biology, however, data from patients treated with a new targeted agent often show that one or both of these assumptions are false. This paper provides a Bayesian randomized group sequential enrichment design that compares an experimental treatment to a control based on survival time and uses early response as an ancillary outcome to assist with adaptive variable selection and enrichment. Initially, the design enrolls patients under broad eligibility criteria. At each interim decision, submodels for regression of response and survival time on a baseline covariate vector and treatment are fit; variable selection is used to identify a covariate subvector that characterizes treatment-sensitive patients and determines a personalized benefit index, and comparative superiority and futility decisions are made. Enrollment of each cohort is restricted to the most recent adaptively identified treatment-sensitive patients. Group sequential decision cutoffs are calibrated to control overall type I error and account for the adaptive enrollment restriction. The design provides a basis for precision medicine by identifying a treatment-sensitive subpopulation, if it exists, and determining whether the experimental treatment is superior to the control in that subpopulation. A simulation study shows that the proposed design reliably identifies a sensitive subpopulation, yields much higher generalized power compared to several existing enrichment designs and a conventional all-comers group sequential design, and is robust.

A Group Sequential Design and Sample Size Estimation for an Immunotherapy Trial with a Delayed Treatment Effect.

A robust approach to sample size calculation in cancer immunotherapy trials with delayed treatment effect

Designing therapeutic cancer vaccine trials with delayed treatment effect

SPIRIT: A Seamless Phase I/II Randomized Design for Immunotherapy Trials

A Practical Simulation Method to Calculate Sample Size of Group Sequential Trials for Time-to-Event Data under Exponential and Weibull Distribution

Design and Analysis of group-sequential clinical trials based on a modestly-weighted log-rank test in anticipation of a delayed separation of survival curves: A practical guidance

Bayesian Group Sequential Enrichment Designs Based on Adaptive Regression of Response and Survival Time on Baseline Biomarkers.

A Bayesian Group Sequential Design for Randomized Biosimilar Clinical Trials with Adaptive Information Borrowing from Historical Data

A Bayesian Phase I/II Trial Design for Immunotherapy

A two‐stage group‐sequential design for delayed treatment responses with the possibility of trial restart

An Adaptive Trial Design to Optimize Dose-Schedule Regimes with Delayed Outcomes

A Bayesian Design for Phase II Clinical Trials with Delayed Responses Based on Multiple Imputation.

Design and Analysis of Clinical Trials in the Presence of Delayed Treatment Effect

Group sequential designs for clinical trials when the maximum sample size is uncertain

BOIN12: Bayesian Optimal Interval Phase I/II Trial Design for Utility-Based Dose Finding in Immunotherapy and Targeted Therapies.

A Simulation-free Group Sequential Design with Max-combo Tests in the Presence of Non-proportional Hazards

Seamless Phase II/III Design: a Useful Strategy to Reduce the Sample Size for Dose Optimization

Time-to-event Model-Assisted Designs for Dose-Finding Trials with Delayed Toxicity

Optimal Marker-Adaptive Designs for Targeted Therapy Based on Imperfectly Measured Biomarkers

Adaptive two-stage seamless sequential design for clinical trials

TITE‐BOIN12: A Bayesian Phase I/II Trial Design to Find the Optimal Biological Dose with Late‐onset Toxicity and Efficacy